Roche Corleen M. 4

What Happened

• Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics, was granted 132,200 restricted stock units (RSUs) on March 9, 2026. The grant is reported as a derivative award with a $0 per-unit grant price (no cash paid). RSUs are contingent rights to receive common stock and are not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (appears timely).
• Transaction type/code: Award/Grant (A) — 132,200 RSUs; Reported price: $0.00.
• Shares owned after the transaction: not disclosed in the provided filing details.
• Footnote summary:
  • Each RSU converts to one share of Iovance common stock upon settlement.
  • Vesting schedule: subject to continued employment — one‑third vests on the 1‑year anniversary of the grant; the remaining two‑thirds vest in eight equal quarterly installments over the next two years, starting with the first quarter after the first anniversary.
• No indication of tax-withholding sale, 10b5-1 plan, or late filing in the provided data.

Context

• RSU grants are a common form of long-term compensation intended for retention; they do not represent an immediate cash transaction or insider purchase. Once RSUs vest and convert to shares, the insider may hold or sell those shares subject to company policy and disclosure rules.